Mayne Pharma Group Limited (#ASX: $MXY) announced the New Drug Application for E4/DRSP to prevent pregnancy has been accepted for review by the US FDA. The FDA is expected to complete its review in the H1 2021. https://t.co/9wAGm1w9YD. #Pharmaceutical #stocks #stockstowatch #drug https://t.co/B9tn6AEDBI